Form 4: Aligos Therapeutics Director Acquires Stock Options

James Paul Scopa, a Director at Aligos Therapeutics, Inc., acquired stock options for 5,860 shares of common stock on June 25, 2026.

Summary

• James Paul Scopa, a Director at Aligos Therapeutics, Inc. (ALGS), acquired 5,860 stock options on June 25, 2026.
• These options have an exercise price of $5.50 and an expiration date of June 25, 2036.
• The options are set to vest 100% on the first anniversary of the grant date or immediately prior to the 2027 annual meeting, contingent on continued service.
• Following this transaction, Scopa beneficially owns 5,860 shares of common stock directly.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, as it represents a standard insider stock option grant to a director, indicating alignment of interests and confidence, but without new financial performance data.

Positives

• Director James Paul Scopa has acquired stock options, indicating continued commitment and potential future upside in Aligos Therapeutics.
• The acquisition of options at an exercise price of $5.50 suggests a belief in the company's future stock performance exceeding this level.

Risks

• The vesting of the options is contingent on continuous service to the Issuer, meaning any departure before the vesting date would result in forfeiture.
• The value of the options is subject to market fluctuations and the company's future performance.

Future Outlook

The stock options acquired by Director James Paul Scopa are set to vest fully on the earlier of the first anniversary of the grant date or immediately prior to the annual meeting in 2027, provided he remains in continuous service to the Issuer. This indicates a forward-looking incentive tied to continued employment and company performance.

Industry Context

StockSavvy.ai notes that Form 4 filings, such as this one from Aligos Therapeutics, are standard disclosures for insider transactions. The acquisition of stock options by a director is a common incentive mechanism in the biotechnology sector, aligning management's interests with those of shareholders and signaling confidence in future growth.

Stakeholder Impact

• Shareholders: The acquisition of options by a director can be seen as a positive signal of management's commitment and belief in the company's future value, potentially aligning their interests with shareholders.
• Employees: The vesting condition tied to continuous service reinforces the importance of employee retention and performance for the company's success.

Next Steps

• Director James Paul Scopa must remain in continuous service to Aligos Therapeutics until the vesting date of the stock options.
• The options will become exercisable on the earlier of the first anniversary of the grant date or immediately prior to the 2027 annual meeting.

Key Dates

Keywords

Aligos Therapeutics, ALGS, Form 4, Stock Options, Insider Transaction, Director, Beneficial Ownership, Securities Exchange Act